Mr. Speaker, my colleague from London—Fanshawe has asked an excellent question, a question I posed for the trade minister and for many Liberals in the House. No one seems to want to address it. No one wants to talk about the fact that 25% of the implementing legislation we are talking about today consists of patent changes that will cost Canadians more money.
The minister has said that it will be eight to 10 years off. Eight to 10 years is not a long span of time. Many drugs will be coming forward to be patented, such as the biosimilar drugs. These drugs could be the future. They could cure cancer and diabetes. When those drugs are patented, Canadians will have to pay more. The government has absolutely no plan to deal with that cost to the provinces. There was mention of that under the previous Conservative government, but absolutely nothing under the Liberals. I have yet to receive an answer to that question.
We would be hard pressed to find one Canadian outside of the chamber who thinks that signing a trade deal that increases the cost of drugs for them, their neighbours and loved ones is a good idea. No one thinks this is a good idea.
The other issue is pharmacare. Canadian nurses have told us quite clearly that we will likely never see pharmacare in our country, that we will be sued for trying to bring such a plan into Canada. Many countries in the EU already have—